Exact Mass: 607.2814880000001
Exact Mass Matches: 607.2814880000001
Found 136 metabolites which its exact mass value is equals to given mass value 607.2814880000001,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Chymostatin
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D015842 - Serine Proteinase Inhibitors
Chymostatin
PC(2:0/5-iso PGF2VI)
PC(2:0/5-iso PGF2VI) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/5-iso PGF2VI), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-iso Prostaglandin F2alpha-VI at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(5-iso PGF2VI/2:0)
PC(5-iso PGF2VI/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(5-iso PGF2VI/2:0), in particular, consists of one chain of one 5-iso Prostaglandin F2alpha-VI at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
1beta-Acetoxy-9beta-benzoyloxy-8alpha-isobutanoyloxy-13-nicotinoyloxy-beta-dihydroagarofuran
Glu His His Trp
Glu His Trp His
Glu Trp His His
Phe Lys Gln Trp
Phe Lys Trp Gln
Phe Gln Lys Trp
Phe Gln Gln Trp
Phe Gln Trp Lys
Phe Gln Trp Gln
Phe Trp Lys Gln
Phe Trp Gln Lys
Phe Trp Gln Gln
His Glu His Trp
His Glu Trp His
His His Glu Trp
His His Trp Glu
His Trp Glu His
His Trp His Glu
Lys Phe Gln Trp
Lys Phe Trp Gln
Lys Gln Phe Trp
Lys Gln Trp Phe
Lys Trp Phe Gln
Lys Trp Gln Phe
Asn Arg Arg Tyr
Asn Arg Tyr Arg
Asn Tyr Arg Arg
Gln Phe Lys Trp
Gln Phe Gln Trp
Gln Phe Trp Lys
Gln Phe Trp Gln
Gln Lys Phe Trp
Gln Lys Trp Phe
Gln Gln Phe Trp
Gln Gln Trp Phe
Gln Trp Phe Lys
Gln Trp Phe Gln
Gln Trp Lys Phe
Gln Trp Gln Phe
Arg Asn Arg Tyr
Arg Asn Tyr Arg
Arg Arg Asn Tyr
Arg Arg Tyr Asn
Arg Tyr Asn Arg
Arg Tyr Arg Asn
Trp Glu His His
Trp Phe Lys Gln
Trp Phe Gln Lys
Trp Phe Gln Gln
Trp His Glu His
Trp His His Glu
Trp Lys Phe Gln
Trp Lys Gln Phe
Trp Gln Phe Lys
Trp Gln Phe Gln
Trp Gln Lys Phe
Trp Gln Gln Phe
Tyr Asn Arg Arg
Tyr Arg Asn Arg
Tyr Arg Arg Asn
N-[6-2(1,1-DIMETHOXY)ETHOXY]-5-(2-METHOXYPHENOXY) [2,2?-BIPYRIMIDIN]-4-YL]-4-(1,1-DIMETHYLETHYL) BENZENESULFONAMIDE
7-[4-fluorophenyl]-6-isopropyl)-2-(N-Methyl-N-MethylSulfonyl amino)pyrimidine-5-yl]-(3R)-3-(terbutyldimethylsilyloxy)-5-oxo-6E-heptane acid,Methyl ester
C29H42FN3O6SSi (607.2547484000002)
(2R)-2-{[(5Z)-7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl}hept-5-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
4-fluoro-N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
2-[(2R,4aS,12aS)-8-[(3-methoxyphenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(4-propan-2-ylphenyl)acetamide
C32H37N3O7S (607.2352092000001)
4-fluoro-N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3R,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
4-fluoro-N-[(3S,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl(propyl)amino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]benzenesulfonamide
C31H46FN3O6S (607.3091188000001)
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxydodeca-4,8-dien-2-yl]butanamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytetradeca-4,8-dien-2-yl]acetamide
N-[(4E,8E)-1-[3,4-dihydroxy-6-(hydroxymethyl)-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3-hydroxytrideca-4,8-dien-2-yl]propanamide
2-[(9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl]-sn-glycero-3- phosphocholine
A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as (9S,11R)-epidioxy-(15S)-hydroperoxy-(5Z,13E)-prostadienoyl.
[(1s,2r,5s,6s,7s,8s,9s)-5-(acetyloxy)-7-(benzoyloxy)-2,10,10-trimethyl-8-[(2-methylpropanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-6-yl]methyl pyridine-3-carboxylate
(2s)-2-{n-[(s)-(2-imino-1,3-diazinan-4-yl)({[(1s)-3-methyl-1-{[(2s)-1-oxo-3-phenylpropan-2-yl]-c-hydroxycarbonimidoyl}butyl]-c-hydroxycarbonimidoyl})methyl]-(c-hydroxycarbonimidoyl)amino}-3-phenylpropanoic acid
[8-(acetyloxy)-7-(benzoyloxy)-2,10,10-trimethyl-5-[(2-methylpropanoyl)oxy]-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-6-yl]methyl pyridine-3-carboxylate
(2r,3s)-n-[(s)-[(2r,6s)-6-[(2s,3s)-3-[(3r)-6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydro-2-benzopyran-3-yl]-2-hydroxybutyl]-5,5-dimethyl-4-oxooxan-2-yl](methoxy)methyl]-2-hydroxy-3-(hydroxymethyl)-5-methylhex-5-enimidic acid
(4r,7r)-n-[(2s)-1-[(3s,8ar)-3-benzyl-1,4-dioxo-tetrahydro-3h-pyrrolo[1,2-a]pyrazin-2-yl]-3-methyl-1-oxopentan-2-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboximidic acid
1,3,4-Tridehydrofangchinolium hydroxide
{"Ingredient_id": "HBIN001033","Ingredient_name": "1,3,4-Tridehydrofangchinolium hydroxide","Alias": "1,3,4-tridehydrofangchinolium hydroxide","Ingredient_formula": "C37H39N2O6","Ingredient_Smile": "CN1CCC2=CC(=C3C=C2C1CC4=CC=C(C=C4)OC5=C(C=CC(=C5)CC6=[N+](CCC7=CC(=C(C(=C76)O3)O)OC)C)OC)OC","Ingredient_weight": "607.78","OB_score": "37.06124462","CAS_id": "NA","SymMap_id": "SMIT00943","TCMID_id": "32105","TCMSP_id": "MOL004013","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}